Clinical Trials Directory

Trials / Unknown

UnknownNCT01776489

Evaluation of the Sphingolipid Metabolite S1P as a Novel Biomarker in Food Allergy

The Role of Sphingosine-1-phosphate in Food Allergy - Biomarker for Disease Severity and Anaphylaxis Outcome

Status
Unknown
Phase
Study type
Observational
Enrollment
70 (estimated)
Sponsor
Medical University of Vienna · Academic / Other
Sex
All
Age
12 Months – 17 Years
Healthy volunteers
Not accepted

Summary

Food allergies represent an increasing health concern in the industrialized countries and especially affect pediatric patients. In this population adverse reactions against food compounds can lead to anaphylactic reactions. Despite substantial research efforts, clinical markers predicting disease severity and symptoms are missing to date. Recent studies have revealed that sphingolipids, especially sphingosine-1-phosphate (S1P), play an essential role in allergy. It was reported that asthmatic patients have higher S1P levels in bronchiallavage fluids after allergen challenge. First experimental studies revealed a correlation of S1P and the outcome of anaphylaxis. Furthermore, we have shown in our recent mouse study that S1P homeostasis is pivotal for food allergy induction and effector cell response. Therefore, it is the aim of the presented pilot project to evaluate whether S1P serum titers are altered in food allergic children and if the S1P levels correlate with the outcome of anaphylaxis during double blind placebo controlled food challenges (DBPCFCs).

Conditions

Timeline

Start date
2011-12-01
Primary completion
2017-01-01
Completion
2017-01-01
First posted
2013-01-28
Last updated
2015-12-11

Locations

1 site across 1 country: Austria

Source: ClinicalTrials.gov record NCT01776489. Inclusion in this directory is not an endorsement.